Menu
Back to User profile » Dr Gabriel Tremblay
Papers published by Dr Gabriel Tremblay:
US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
Dolph M, Tremblay G, Leong H
ClinicoEconomics and Outcomes Research 2021, 13:493-502
Published Date: 10 June 2021
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A
ClinicoEconomics and Outcomes Research 2019, 11:673-681
Published Date: 12 November 2019
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A
ClinicoEconomics and Outcomes Research 2019, 11:551-565
Published Date: 6 September 2019
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
Tremblay G, Dolph M, Bhor M, Said Q, Roy A, Elliott B, Briggs A
ClinicoEconomics and Outcomes Research 2018, 10:715-721
Published Date: 5 November 2018
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, Briggs A
ClinicoEconomics and Outcomes Research 2018, 10:705-713
Published Date: 1 November 2018
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M
Cancer Management and Research 2018, 10:1319-1327
Published Date: 22 May 2018
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G
Breast Cancer: Targets and Therapy 2018, 10:69-78
Published Date: 4 May 2018
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G
Cancer Management and Research 2018, 10:1015-1025
Published Date: 4 May 2018
Systematic review of health state utility values for acute myeloid leukemia
Forsythe A, Brandt PS, Dolph M, Patel S, Rabe APJ, Tremblay G
ClinicoEconomics and Outcomes Research 2018, 10:83-92
Published Date: 25 January 2018